Changing forms of HIV-related stigma along the HIV care and treatment continuum in sub-Saharan Africa: a temporal analysis

O Bonnington,1 J Wamoyi,2 W Ddaaki,3 D Bukenya,4 K Ondenge,5 M Skovdal,6,7 J Renju,1,8 M Moshabela,9,10 A Wringe1

ABSTRACT

Objectives Stigma remains pervasive for people living with HIV (PLHIV) in sub-Saharan Africa, undermining care engagement. Using everyday, biographical and epochal temporalities, we explored the manifestation of stigma at different stages of the HIV care continuum in seven health and demographic surveillance sites in Eastern and Southern Africa.

Methods Between 2015 and 2016, we conducted qualitative in-depth interviews with 264 PLHIV, 54 health providers and 48 family members of people who had died from HIV. Topic guides explored experiences of HIV testing, care and treatment services. Data were analysed thematically, aided by NVivo 10.

Results In everyday time across these communities, stigma was evident in the presence of gossiping and the relative absence of supportive interpersonal discourse, which fuelled judicious disclosure. This was especially disruptive at testing, counselling and early antiretroviral therapy adherence stages of care. Biographical time framed everyday stigma events, highlighting the dilemma of disclosure in relation to sexual relationship norms, as well as the interfacing of age and healthcare continuum points. Epochal patriarchal relations gave a structural context to everyday and biographical stigma dynamics. Historical shifts to social acceptance of PLHIV within these communities, while positive, were complicated by stigma in everyday life and in respect of biographical goals like having a family. Moreover, low community-level resistance to HIV-related stigma jeopardised stigma reduction strategies.

Conclusions Despite improvements to HIV care services, stigma remains pervasive across the HIV care continuum in these sites. Context-specific interventions are needed to address stigma and discrimination of PLHIV within the community and in health services, and greater reflection is required to ensure policies aiming to expand HIV treatment do not exacerbate stigma and result in negative HIV outcomes.

INTRODUCTION

Stigmatisation involves individual, cultural and structural processes which, through the use of power, combine to produce negatively valued difference.1 HIV-related stigma may hinder attempts to eliminate AIDS by 2030.2 Therefore, the 2016 UN General Assembly Political Declaration on Ending AIDS has set out a target of eliminating HIV-related stigma and discrimination by 2020. This ambitious target follows earlier hopes that the UN AIDS target problematic. For instance, Roura et al noted the emergence of a stigma paradox 2 years after ART availability in rural Tanzania. On the one hand, PLHIV were seen as less burdensome by themselves and others, leading to decreased self-stigma (ie, internalising public stigma) and increased social support, which helped normalise HIV and increased voluntary counselling and testing (VCT) uptake. This is supported by other studies from sub-Saharan Africa in respect of decreasing public stigma3 and increasing the coping skills of PLHIV.4 On the other, new sources of stigma emerged whereby fears of sexual transmission were exacerbated, fuelling moral outrage, and a persistence in blame for being ‘irresponsible’ in spreading the virus through sexual activity abounded. This, in turn, led to widespread anticipated stigma (ie, fear of being stigmatised), othering and a collective denial that reduced VCT uptake.

Most qualitative research exploring the relationship between stigma and accessing HIV services has focused on how it influences HIV testing uptake.5 6 11 12 Few studies have explored the effect of stigma on PLHIV’s engagement with HIV services once diagnosed and expected to initiate ART, and adhere to lifelong pill-taking and clinic visits.13 14 Additionally, most stigma studies have been quantitative rather than qualitative,11 15 16 often looking at public stigma5 6 rather than experienced stigma (ie, the actual experience of discrimination or prejudice) and anticipated stigma among PLHIV. Furthermore, stigma studies in the context of ART roll-out have tended to focus on one country.7 17 18 19 20 However, if HIV-related stigma is going to be reduced, there is a need to understand how stigma manifests and is experienced and anticipated at different stages of HIV care. Moreover, it is imperative that this is understood across the health service and policy contexts of different epidemics. Understanding the geographical and care continuum manifestations of stigma enables anti-stigma interventions to be more efficiently targeted.

Three overlapping stigma temporalities

Essential to this is having a nuanced understanding of the temporality of stigma events. Stigma studies focusing on the effect of ART on VCT stages tend to have a singular view of time (ie, either before
and after new treatment, or the point in time when testing occurs), rather than one where overlapping modalities of time effect the contexts and concerns of PLHIV. In contrast, this paper uses three perspectives on time: everyday, biographical and epochal. These are not philosophically discrete, detached ways within which stigma dynamics play out, but imbricated ones that flow into and influence each other. An analytical understanding of the role of time—in combination with social and cultural structures and human agency—provides clues for antistigma practices.

Everyday time concerns the description, immediacy and repetition of daily stigma events. Some questions PLHIV might navigate in everyday time are: How is HIV discussed day-to-day in public spaces? Given what others know about me, will I experience stigma today if I socialise with friends?

Biographical time is slightly different to the quotidian repetition of everyday stigma. Pertinent questions here include: When should people get tested for HIV during their lifetimes? When and to whom should they disclose their status? Should they start treatment when advised? The key question cutting through all of these is ‘What is at stake within this and future biographical moments—will my life chances and projects be limited in some way if I am associated with HIV?’

Epochal or historical time relates to whether conditions influencing HIV-related stigma are stable and enduring, or elaborated and transformed. So, for instance, is gossiping about PLHIV a practice that is being observed less nowadays than in the past? Are communities unified and enabled to challenge stigma, or is stigma resistance still sporadic and individualised? How have developments in treatment availability and coverage influenced the level and nature of stigmatising interactions?

Using these temporalities, we aim to investigate how HIV-related stigma manifests in PLHIV’s accounts of their HIV care across seven rural locations in six sub-Saharan African countries and how these experiences shape their treatment engagement.

METHODS

Settings and sample

This paper draws upon qualitative data from in-depth interviews conducted in a multicountry study (the ‘Bottlenecks’ study) exploring the interaction of PLHIV and HIV care services. Additional methodological details concerning the Bottlenecks study can be found in the online-only supplement found within the editorial http://dx.doi.org/10.1136/sextrans-2017-053172. Ethical approval was obtained from London School of Hygiene & Tropical Medicine (LSHTM) (Ref: 10389) and by local ethics boards at the study locations. Informed and written consent was obtained from all participants. The study took place in Karonga (Malawi), Rakai and Kyamulibwa (Uganda), Kisesa (Tanzania), Kisumu (Kenya), Manicaland (Zimbabwe) and uMkhanyakude (South Africa). Through health and demographic surveillance site (HDSS) datasets and ART clinics, we purposively sampled 264 PLHIV and 48 family members of deceased people with HIV to achieve a broad distribution of sex, age and care history. Family members were identified through HDSS verbal autopsy reports. Additionally, 54 healthcare workers were purposively sampled across the sites to ensure a range of perspectives on the provision of HIV services from different cadres (see table 1). Further information can be found in the online supplementary file.

Data collection and analysis

Fieldworkers were trained in each location. They administered a short screening tool before conducting each in-depth interview to ensure participant eligibility and to obtain diagnosis and treatment history of PLHIV. Face-to-face in-depth interviews, conducted in local languages, were chosen owing to the sensitive and personal nature of information being discussed. Topic guides for PLHIV explored experiences of interactions with healthcare services throughout the care continuum, the salience of community health issues and HIV-related stigma. Some repeat interviews were done to build rapport and discuss more sensitive issues. Interviews with family members of the deceased focused on the circumstances that contributed to their loved ones’ deaths. Healthcare provider interviews solicited reflections on engaging PLHIV and delivering HIV services. Details of how these topics were generated can be found in the online-only supplement. Interviews lasted approximately 45–90 min and took place in participants’ homes or private clinic areas. Data were collected between October 2015 and April 2016. Interviews were audio-recorded, then anonymised, and either summarised into detailed reports (Kyamulibwa) or transcribed (Karonga, Kisesa, Rakai, Kisumu, Manicaland, uMkhanyakude) and translated into English. Summaries were done in Kyamulibwa due to researchers at this site being historically trained in this method. All data were stored in secure password-protected locations. Participants were recruited until thematic saturation was reached.

A latent thematic analysis was conducted, which entails a process of identifying and analysing patterns within qualitative data beyond surface meanings. A broad analytical framework

| Table 1 Description of study participants by site |
|-----------------------------------------------|
| **Country** |
| **Uganda** |
| **Kenya** |
| **Tanzania** |
| **Malawi** |
| **Zimbabwe** |
| **South Africa** |
| **Total** |
| **HDSS** | **Rakai** | 6 | 15 | 15 | 6 | 8 |
| **HCW** | 5 | 15 | 15 | 6 | 8 |
| **HCW** | 8 | 10 | 15 | 6 | 11 |
| **Kisesa** | 7 | 13 | 14 | 4 | 6 |
| **Kisesa** | 5 | 9 | 27 | 4 | 6 |
| **Karonga** | 4 | 16 | 35 | 8 | 6 |
| **uMkhanyakude** | 19 | 16 | 17 | 6 | 6 |
| **Total** | 54 | 87 | 139 | 38 | 48 |

| **Person living with HIV** |
| **Never ART** | 15 | 15 | 6 | 8 |
| **On ART** | 15 | 15 | 6 | 8 |
| **LTFU†** | 6 | 6 | 11 | 11 |
| **Family member of deceased** |
| **Country** |
| **Uganda** |
| **Kenya** |
| **Tanzania** |
| **Malawi** |
| **Zimbabwe** |
| **South Africa** |
| **Total** |
| **Never ART** | 6 | 15 | 15 | 6 | 8 |
| **On ART** | 15 | 15 | 6 | 8 |
| **LTFU†** | 6 | 6 | 11 | 11 |
| **Family member of deceased** | 8 | 8 | 11 | 11 |

†Lost to follow up from a HIV clinic for >90 days;
ART, antiretroviral therapy; HCW, healthcare Worker; HDSS, health and demographic surveillance sites; LTFU, lost to follow up.

2 Bonnington O, et al. Sex Transm Infect 2017;Q:1–6. doi:10.1136/sextrans-2016-052975
for coding stigma-related issues within the dataset was established by OB, based on inductive coding of randomly selected transcripts and deductive categories derived from general stigma theory and specific concepts (anticipated stigma, public stigma, experienced stigma and self-stigma), as defined above. This was initially populated and adapted by site coordinators who coded their site’s data with the aid of NVivo 10. OB then conducted a further layer of deductive coding on the superordinate stigma themes from each site to analyse them in respect of the aforementioned temporal perspectives. Ongoing data analysis, emerging hypotheses and the analytical approach were discussed with site coordinators during regular meetings.

RESULTS

Stigma in everyday time

Across the sites, stigma within the daily routines and repetitive dilemmas of PLHIV’s lives included: (1) the immediate presence of stigma in everyday situations, manifest as repeated gossiping, mocking and laughing, and (2) the relative absence of supportive interpersonal discourse, which fuelled information management and judicious disclosure.

The presence of stigma, across the sites, typically materialised in anticipated gossiping, though numerous examples of experienced gossiping existed too. While some PLHIV ignored community gossip and engaged in care, for others, its insidiousness influenced their termination or intermittence of treatment:

After the test I was told that I have the virus and I accepted it. I went back home and when we were bathing in the rivers I was sickly and they laughed at me. You see, this made me stop treatment. (Male, PLHIV, on ART, Zimbabwe)

Public stigma (occasionally enacted by healthcare workers) disrupted PLHIV’s transitioning throughout the care and treatment continuum, but especially during testing and early counselling, and also initial ART adherence. Central to fear of gossip was the lack of privacy and confidentiality experienced daily at community clinics and hospitals:

How will they [neighbours] regard me being in the queue there, on the bench waiting for the medicines, or when I’ve gone for testing...how will they think of me? (Male, PLHIV, on ART, Tanzania)

Fear of gossiping and mocking prompted some PLHIV to retreat from clinics or travel long distances to those far away from their communities:

I come to a far away clinic, no one will know that I have come here to take drugs. (Female, PLHIV, on ART, Kenya)

Stigma in biographical time

Biographical time frames everyday stigma events to highlight the dilemma of disclosure in relation to sexual relationship norms, as well as the interfacing of age and healthcare continuum points.

Disclosure and relationships

The dilemma of disclosure within—and its threat to—heterosexual and marital relations, especially for younger people, was vexed and salient. One young Ugandan woman recounted: ‘If you had no man, you wouldn’t get anyone [if they knew your status]. If someone loved you, [your friends] would say to them, “that one is sick”’. This issue complicated couple-testing policies at each location.

They [pregnant women] are all accepting to get tested. We have a few problems where they do not want to get tested or after getting tested they do not want their results. If that person takes the results she might refuse to take treatment... this is mostly done by the young mothers who have recently got married. They are afraid to test positive and afraid to tell their husbands...afraid that the marriage might be broken. (Healthcare worker, Zimbabwe)

Within the sample, complete and ongoing concealment in interpersonal relationships was rare. Yet, disclosure was individual and time-sensitive, a biographical step-change that was risky across relationships. Potential social support from partners, friends, family and neighbours, often forthcoming consequent upon disclosure, simultaneously posed a risk of discrimination and blame:

After finding out that I was positive, and my sister in law scolding me, I saw that it was better someone dies rather than feeling the pain of being rudely talked to. (Female, PLHIV, on ART, Kenya)

That said, when some PLHIV did not disclose, they continued to hear negative comments from their loved ones about PLHIV, became alienated from other PLHIV and sometimes missed clinical appointments:

The person I stay with—my mother in law—I have not disclosed to her. So finding time to come here [clinic] is a bit difficult, so most of the times I come late, at times I miss coming. (Female, PLHIV, on ART, Kenya)

We still have a problem especially us young males, even me. Before I tested positive...I didn’t like someone who is HIV positive. I remember when another guy disclosed his status, while we were busy eating meat, I chose to stop eating with them. What I used to see is people are talking badly about HIV even though they are HIV positive. Now I can see why they do that; they want to protect their names from being known that they are HIV positive. (Male, PLHIV, on ART, South Africa)

Family members tended to offer most support to PLHIV after disclosure, across the sites. However, some PLHIV only disclosed to partners, especially when there was family discord. Indeed, PLHIV sometimes concealed their diagnosis and treatment from their family members even after ART initiation.

Age and HIV care experience

The second way biographical time contextualised everyday stigma events was in respect of age and point along the care and treatment continuum. In this respect, gossiping was less affecting for those over 40 and those more stable on ART, perhaps because some goals (eg, courtship and reproduction) had already been achieved. That said, some older people were marginalised and considered already dead by their family members. A healthcare worker in Kisesa recounted an older woman’s experience:

After further encouragement, her family members visited, they refused to be supportive and started to divide the old woman’s possessions as she watched...They told her they will stay distant until she passes away then take her remaining possessions.

Moreover, some older people reported unease at clinics where they were often outnumbered by younger people whom, they imagined, speculated about their sexual activity:

We old people mix with children there [hospital]... people tend to think about how we old people got infected with this disease. (Male, PLHIV, on ART, Malawi)
Stigma in epochal time

Epochal patriarchal relations gave a structural context to everyday and biographical stigma dynamics. Historical shifts to social acceptance of PLHIV within these communities, while positive, were complicated by stigma in everyday life and in respect of biographical goals like having a family. Moreover, low community-level resistance to HIV-related stigma, and contradictory strategies, such as integrating or separating patients with HIV in clinics, jeopardised and confused stigma reduction strategies.

Patriarchy
In combination with a reluctance to disclose, men were often able to mobilise patriarchal structures to avoid testing, whether alone or part of a couple.

Interviewer: Did you test together with your husband?
Participant: No, he does not allow, he does not accept. He does not tell me. I got this feeling that he is like me [HIV+] but fears to tell me. (Female, PLHIV, diagnosed not in care, Uganda)

Moreover, men often insisted that their partners get tested and disclose first, which they used to absolve themselves from any part in bringing HIV into relationships. HIV-positive women sometimes hid their status or stopped pill-taking for fear of domestic abuse or divorce. One young woman in Karonga, on ART while pregnant, hid her ARVs in a bag of flour, scared that her husband would have beaten her up or even killed her if he had discovered her status.

Normalisation?
Notwithstanding enduring issues of patriarchy, there were signs of increasing social acceptance of HIV over historical time within these communities. HIV was acknowledged as widespread, even ‘normal’, and no longer viewed uniformly as a death sentence in the age of ART; many participants were ‘not shocked’ at being diagnosed.

I just felt normal about having [AIDS], like it was a normal thing because it’s not just me who has it…why would I be shocked? It has become a disease for everyone. (Female, PLHIV, on ART, Tanzania)

There were suggestions that marginalisation of HIV was decreasing across these communities. While any historical decline of marginalisation might seem positive, it runs in tandem with the persistence and power of everyday gossiping and laughing mentioned above.

Each household where there is person living with HIV, those people accept it, they understand now. But where there is no one with HIV they see it as a joke. (Female, PLHIV, Diagnosed but not on ART, Zimbabwe)

Indeed, some of participants’ discourse suggested a hope for idealised situation rather than an experienced reality. Relatedly, some PLHIV who described this epochal shift to social acceptance simultaneously struggled with disclosure. Also, some healthcare workers went so far as to claim that ‘currently there is no stigma’ (Karonga) in their communities allowing people to test more freely. Yet, this view sometimes contrasted markedly with the daily experiences of PLHIV, shown above.

Challenging stigma?
Community-level challenges to stigma remain low and fragmented across all sites, suggesting epochal stasis, due to a lack of resources. Support most often came privately from immediate family and friends:

My husband, once I had told him… he was the one who advised me to just come and take drugs, that it was good. (Female, PLHIV, on ART, Kenya)

That said, some older PLHIV reported instances of community members being fined and sanctioned for gossiping (eg, in Malawi, Zimbabwe, Uganda), and there were a few examples of local opinion leaders organising well-attended public HIV discussions:

Church leaders, like priests and catechists, preached against community stigma in their communities. (Healthcare worker, Uganda)

In the current epoch, increased visibility of HIV-related activities in the community can have both positive and negative effects on stigma. For example, integrated healthcare services were considered by some PLHIV and healthcare workers as destigmatising in Kyamulibwa (because it reduced ‘othering’), but stigmatising in Kisesa and Karonga (because of lack of privacy).

We mixed HIV patients with general ones because of stigma. Patients were afraid of being seen coming from the counselling room. (Healthcare worker, Uganda)

DISCUSSION

Within these communities, HIV-related stigma persists in everyday, biographical and epochal time. These temporal framings shed light on why PLHIV cycle in and out of care, why the 2020 UN stigma reduction target is ambitious and why stigma persists in the age of ART.

Everyday stigma events included gossiping, laughing and mocking from community members, and relatively absent supportive community HIV-related discourse. This contributed to delayed uptake of testing and intermittent postdiagnosis care engagement, supporting findings from other recent single-country and multicountry analyses. Continued public concealment of seropositivity, especially during earlier stages of care, influences the absence of tolerant discourse. However, few PLHIV disclosed to no one, as has been observed elsewhere. The absence of constructive discussion of HIV in public spheres has previously been reported by Campbell et al in South Africa. When gossip is the main presence of HIV discourse in public life, it restricts the daily support for PLHIV. Moreover, persisting forms of everyday stigma frustrate the biographical goal of HIV stabilisation and the epochal one of AIDS elimination. Private support within families and friendships has enabled greater acceptance, but this needs to translate into everyday advocacy and accepting discourses in public too.

Healthcare staff, policy-makers and community leaders should help PLHIV understand everyday experiences of stigma in light of wider epochal shifts to social acceptance; where PLHIV are unable to detect these changes in their everyday lifeworlds, then their care engagement may be undermined.

Biographical time, especially in respect of pressures to partake in socially and sexually important projects and practices, contextualises why everyday stigma events are important throughout the life course and at different points along the care and treatment continuum, particularly during testing and ART adherence. Healthcare workers and policy-makers must recognise the importance of HIV-related stigma to compensate for individuals’ everyday experiences of stigma.
biographical life goals, such as sexual relationships and child-rearing, and work with PLHIV and their partners to find accepting solutions. The finding that HIV-related stigma is affected by epochally persisting gender and socioeconomic inequalities, within these communities, reflects earlier studies and indicates the importance of challenging structural stigma in respect of enduring relations of poverty. It should be acknowledged that disclosure in patriarchal and sexist contexts may not be of benefit to PLHIV. Interventions need to be targeted at gender structures and different age groups throughout the life course and specific community contexts. Our findings also mirror those of Church et al who noted the complex relationship between models of HIV care (stand-alone or integrated) and stigma; practical guidance for healthcare workers to minimise stigma across the different models is therefore needed. Notwithstanding the effect of these epochally entrenched and complex conditions on HIV-related stigma, it appears a combination of successful health education, improvements to health services and the provision of ART has partially tackled HIV-related stigma and helped normalise HIV. To go further, there is a great need for village leaders and clinical staff to be supported—financially, legally and normatively—to innovate new ways of generating community discussion and informing policy. Moreover, HIV healthcare should be delivered through flexible community outreach, and engagement techniques should be developed for those who may avoid such visits for fear of being exposed as HIV-positive to neighbours. To insist that PLHIV attend clinics to obtain treatment is to fail to acknowledge the importance of stigma in everyday, biographical and epochal time: the consequence can be that PLHIV wait until they are desperate or die before they get help.

Intractable epochal structures that facilitate stigma, or make no inroads into its mitigation, need to be tackled by a concerted collective effort, which policy-makers need to be part of. Central to this will be investment in community, national and international interventions to destigmatise. As social contact interventions, in the context of improving HIV-related education, appear to offer optimistic avenues for HIV-related stigma reduction, there is a need to continue health education efforts and create considered public interactions between those infected and those who are not across these communities.

Our study has several strengths and limitations. Experienced, local research teams and access to HDSS databases enhanced recruitment and data collection of PLHIV, especially those who were no longer in care. While the generalisability of our findings is limited by the small sample size, cross-country analysis showed a considerable commonality across the research sites, which may be generalisable to other rural populations in sub-Saharan Africa. Participants had some difficulty discussing sensitive issues and experiences; however, this was minimised by ensuring confidentiality and by using trained, local interviewers of different genders and ages who avoided judgemental reactions. People experiencing most extreme or violent forms of stigmatisation were perhaps most likely to be under-represented in the study, for example, those lost to follow-up.

CONCLUSION
Future HIV-related stigma research would benefit from being sensitive to temporality. Consideration of this allows a multifaceted view of HIV-related stigma to emerge throughout the care and treatment continuum, across epidemics. Stigma certainly disrupts testing, but it can also lead to intermitting or terminating postdiagnosis care. In light of historical, biographical and daily persistence of stigma events, there is an urgent need to develop tailored healthcare plans for PLHIV and for greater investment in stigma mitigation.

Key messages
- A novel temporal framing of HIV-related stigma dynamics can usefully situate and interpret experiences of people living with HIV (PLHIV) across the HIV care continuum.
- Everyday time frames HIV-related stigma to show the repetitive presence of gossiping and mocking, but also the relative quotidian absence of supportive interpersonal discourse in public life across these communities.
- Biographical time frames everyday stigma events, highlighting the dilemma of disclosure in relation to sexual relationship norms, as well as the interfacing of age and healthcare continuum points.
- Epochal time shows the importance of persisting patriarchy to stigma experience. There are, however, signs of increasing social acceptance of PLHIV over historical time within these communities.
- There is a great need to focus resources on multilevel resistance to HIV-related stigma that takes account of imbricated temporalities.

Acknowledgements
The authors thank all the participants and fieldworkers who contributed their time and effort to the study. They also acknowledge the support of the Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) representatives at each HDSS who facilitated the implementation of the fieldwork and many other colleagues within the ALPHA Network who made helpful suggestions throughout the design and conduct of the research.

Contributors
All authors contributed to the development of The Bottlenecks Study protocol under the leadership of AW and OB. JW, WD, KB, RS, JR and MM supervised the data collection by trained research assistants and prepared detailed site reports. OB conducted the analysis and prepared the first draft of this manuscript. JW, WD, KB, RS, JR, MM and AW made significant contributions to the manuscript and revised it for intellectual content. All authors have read and commented on the manuscript. All authors have approved the final manuscript, and act as guarantors of the paper.

Funding
The Bottlenecks Study was funded by the Bill and Melinda Gates Foundation (OPP1082114). This paper was also made possible with the support of The Wellcome Trust (085477/2/08/Z and 084401/2/07/Z). Research undertaken in Kisera reported in this publication was supported by the National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institute on Drug Abuse, National Cancer Institute and the National Institute of Mental Health, in accordance with the regulatory requirements of the National Institutes of Health under Award Number U01AI069911 East Africa IeDEA Consortium. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. AW is funded by a Population Health Scientist award, jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCITP2 programme supported by the European Union.

Competing interests
None declared.

Ethics approval
Ethical approval was granted by the London School of Hygiene and Tropical Medicine and the relevant ethics boards at each of the study settings. These were: Malawi National Health Sciences Research Committee #15/5/1427 (Karonga); Medical Research Coordination Committee—MR/3/110/0370 (Kisera); Uganda National Council for Science and Technology—HS1857 (Kyanuwenda) and Office of the President—ADM154/212/01 (Rakai); Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU)—KEMRI/SERU/CH/018/3115 (Kisumu); Medical Research Council of Zimbabwe—MR2C/A/1990; Biomedical Research and Ethics Committee, South Africa, UKZN/BE338/15. Informed and written consent was obtained from all participants.

Provenance and peer review
Commissioned; externally peer reviewed.

Data sharing statement
Access to the data may be provided on request from Dr Alison Wringe (Alison.Wringe@lshtm.ac.uk).
REFERENCES

1. Parker R, Appleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med 2003;57:13–24.

2. UN General Assembly. Political Declaration on HIV and AIDS: On the Fast-Track to Accelerate the Fight against HIV and to End the AIDS Epidemic by 2030. Resolution adopted by the General Assembly, 8 June 2016. A/RES/70/266. Available at: http://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/266. 2016 (accessed 31 Oct 2016).

3. World Health Organization (WHO)/Joint United Nations Program on HIV/AIDS (UNAIDS). Treating 3 million by 2005: making it happen -- the WHO strategy. The WHO and UNAIDS Global Initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva: World Health Organization (WHO)/Joint United Nations Program on HIV/AIDS (UNAIDS), available at: http://www.who.int/3by5/publications/documents/isbn9241591129/en/. 2003. (accessed 31 Oct 2016).

4. Castro A, Farmer P. Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health 2005; 95:53–9.

5. Chan BT, Tsai AC, Siedner MJ. HIV treatment scale-up and HIV-related stigma in sub-Saharan Africa: a longitudinal cross-country analysis. Am J Public Health 2015;105:1581–7.

6. Chan BT, Tsai AC. HIV stigma trends in the general population during antiretroviral treatment expansion: analysis of 31 countries in sub-Saharan Africa, 2003–2013. JAIDS J Acquir Immune Defic Syndr 2016;72:558–64.

7. Roura M, Urassa M, Busza J, et al. Antiretroviral therapy and changing patterns of HIV stigma stigmatisation in Entebbe, Uganda. SocioHealth Illn 2016;38:58–72.

8. Rissa H. Social acceleration: a new theory of modernity. Columbia University Press, 2013.

9. Wringe A, Renju J, Seeley J, et al. Bottlenecks to HIV care and treatment in sub-Saharan Africa: a multicountry qualitative study. Sex Transm Infect 2017; doi:10.1136/sextrans-2017-053172.

10. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.

11. Kranzer K, Govindasamy D, Ford N, et al. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012;15:17383.

12. McMahon SA, Kennedy CE, Winch PJ, et al. Stigma, facility constraints, and personal disbelief: why women disengage from HIV care during and after pregnancy in Morogoro Region, Tanzania. AIDS Behav 2017;21:317–29. doi:10.1007/s10461-016-1505-8.

13. Maman S, Abler L, Parker L, et al. A comparison of HIV stigma and discrimination in five international sites: the influence of care and treatment resources in high prevalence settings. Soc Sci Med 2009;68:2271–8.

14. Rispel LC, Cloete A, Metcalfe CA. ‘We keep her status to ourselves’: experiences of stigma and discrimination among HIV-discordant couples in South Africa, Tanzania and Ukraine. SAHARA J 2015;12:10–17.

15. Campbell C, Nair Y, Mainame S, et al. Dying twice? A multi-level model of the roots of AIDS stigma in two South African communities. J Health Psychol 2007;12:403–16.

16. Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS 2008;22(Suppl 2):S67–79.

17. Nylblade L, Pande R, Mathur S, et al. Disentangling HIV and AIDS stigma in Ethiopia, Tanzania and Zambia. Washington, DC: International Center for Research on Women. 2003.

18. Church K, Wringe A, Fakudze P, et al. Are integrated HIV services less stigmatizing than stand-alone models of care? A comparative case study from Swaziland. J Int AIDS Soc 2013;16:17981.

19. Brown L, Macintyre K, Trujillo L. Interventions to reduce stigma and discrimination settings and interventions. AIDS Educ Prev 2003;15:49–69.

20. Chan BT, Tsai AC. Personal contact with HIV-positive persons is associated with personal disbelief: why women disengage from HIV care during and after pregnancy in Morogoro Region, Tanzania. AIDS Behav 2017;21:317–29. doi:10.1007/s10461-016-1505-8.

21. Mbonye M, Nakamanya S, Birungi J, et al. Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda. BMC Public Health 2013;13:804.

22. Mbonye M, Seeley J, Ssembaja F, et al. Adherence to antiretroviral therapy in Jinja, Uganda: a six-year follow-up study. PLoS ONE 2013;8:e78243.

23. Abrahams N, Jewkes R. Managing and resisting stigma: a qualitative study among people living with HIV in South Africa. J Int AIDS Soc 2012;15:17330.

24. Yuh JN, Ellwanger K, Potts L, et al. Stigma among HIV/AIDS patients in Africa: a critical review. Procedia Soc Behav Sci 2014;140:58–5.

25. Russel S, Zalwango F, Namukwaya S, et al. Antiretroviral therapy and changing patterns of HIV stigmatisation in Entebbe, Uganda. SocioHealth Illn 2016;38:58–72.

26. Rissa H. Social acceleration: a new theory of modernity. Columbia University Press, 2013.

27. Wringe A, Renju J, Seeley J, et al. Bottlenecks to HIV care and treatment in sub-Saharan Africa: a multicountry qualitative study. Sex Transm Infect 2017; doi:10.1136/sextrans-2017-053172.

28. Brauer V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.

29. Kranzer K, Govindasamy D, Ford N, et al. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012;15:17383.

30. McMahon SA, Kennedy CE, Winch PJ, et al. Stigma, facility constraints, and personal disbelief: why women disengage from HIV care during and after pregnancy in Morogoro Region, Tanzania. AIDS Behav 2017;21:317–29. doi:10.1007/s10461-016-1505-8.

31. Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS 2008;22(Suppl 2):S67–79.

32. Nylblade L, Pande R, Mathur S, et al. Disentangling HIV and AIDS stigma in Ethiopia, Tanzania and Zambia. Washington, DC: International Center for Research on Women. 2003.

33. Church K, Wringe A, Fakudze P, et al. Are integrated HIV services less stigmatizing than stand-alone models of care? A comparative case study from Swaziland. J Int AIDS Soc 2013;16:17981.

34. Brown L, Macintyre K, Trujillo L. Interventions to reduce stigma and discrimination settings and interventions. AIDS Educ Prev 2003;15:49–69.

35. Chan BT, Tsai AC. Personal contact with HIV-positive persons is associated with personal disbelief: why women disengage from HIV care during and after pregnancy in Morogoro Region, Tanzania. AIDS Behav 2017;21:317–29. doi:10.1007/s10461-016-1505-8.